Key Drivers
- Strong liquidity
- Persistent losses
- Equity dilution
AIAI Summary
QURE is now a high-expectations regulatory trade on AMT-130 rather than a distant platform biotech: its strong cash runway reduces financing risk, but the ~$2.8B valuation leaves little room for FDA skepticism of the small external-control data set, a narrow label, or weak reimbursement—making approval and launch economics the decisive catalysts.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •Persistent losses
- •Equity dilution
QURE has strong liquidity but remains a high-risk, richly valued investment due to persistent losses, leverage, dilution, and reliance on equity financing.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Support holding
- •Resistance overhead
QURE remains in a short-term downtrend over the last month, with $42.50–$43.10 support and a break above $46.00 needed to improve momentum.
Roughly 14% decline from the
Sentiment & News
Key News Insights:
- •BLA submission
- •U.K. expansion
- •Approval catalyst
uniQure's AMT-130 U.S. and U.K. regulatory filings, including a Priority Review request, position the stock for potential approval-driven upside despite execution risk.
Regulatory acceptance or Priority Review could materially boost QURE, while delays or rejection would pressure shares
Similar Companies in Healthcare
Other companies in the same sector with AI ratings